## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-4.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.26)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors**
- Source: MarketWatch | 20251203T170900 | Somewhat-Bearish | Relevance: 100%
- Zimmer Biomet Holdings Inc. (ZBH) shares fell 1.10% to $93.10 on Wednesday, marking its fourth consecutive day of losses. This occurred despite a generally positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains.

**2. New York State Common Retirement Fund Sells 14,798 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251204T121527 | Neutral | Relevance: 100%
- The New York State Common Retirement Fund has reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.1%, selling 14,798 shares and now owning 166,965 shares valued at approximately $15.23 million. This comes as Zimmer Biomet beat its quarterly EPS estimates but slightly missed revenue expectations, setting FY2025 guidance. Analyst sentiment for the stock is mixed, with a consensus "Hold" rating and an average price target of $109.

**3. Zimmer Biomet (NYSE: ZBH) SVP Lori Winkler Details RSU Vesting and Tax Withheld Shares**
- Source: Stock Titan | 20251204T000837 | Neutral | Relevance: 100%
- Zimmer Biomet Holdings SVP and CHRO Lori Winkler reported the vesting of restricted stock units (RSUs) on November 28, 2025, involving 56.534 and 122.695 shares each, which were settled into common stock at an exercise price of $0. Simultaneously, an equal number of shares were withheld at $97.52 per share to cover FICA and tax obligations due to her retirement eligibility. Following these transactions, Winkler directly holds 6,833 shares, with remaining RSUs vesting in March 2026 and February 2026/2027.

**4. Hsbc Holdings PLC Has $34.05 Million Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251202T094430 | Neutral | Relevance: 100%
- Hsbc Holdings PLC reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.3% in the second quarter, bringing its total holding to 373,505 shares valued at $34.05 million. Other hedge funds also adjusted their positions in ZBH. The article also provides analyst ratings, stock performance data, and details on recent insider trading activity for Zimmer Biomet.

**5. Korea Investment CORP Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251202T112154 | Neutral | Relevance: 98%
- Korea Investment CORP significantly increased its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 12.5% in Q2 2025, bringing its total holdings to 111,789 shares valued at approximately $10.20 million. This increase occurred amidst mixed analyst ratings, with an average "Hold" rating and an average price target of $109, despite recent downgrades from some firms and a "Strong Buy" from another. Zimmer Biomet also reported a slight beat on quarterly EPS and provided FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 7)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Canaccord Genui | $93 | $101 | -8% |
| 2025-11-06 | UBS | $88 | $96 | -8% |
| 2025-11-06 | RBC Capital | $101 | $111 | -9% |
| 2025-11-06 | Barclays | $104 | $105 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Canaccord Genui | main | Hold |
| 2025-11-06 | UBS | main | Sell |
| 2025-11-06 | RBC Capital | main | Outperform |
| 2025-11-06 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 5.9% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Forward P/E 11.0x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (7 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.0B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 11.0 |
| Current P/E | 11.4 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.0% to -0.5% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. MACD histogram positive (0.53), confirming momentum. RSI neutral at 47. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.51% (CS: 47) | Neutral |
| RSI_14 | 46.6 | Neutral |
| MACD Histogram | 0.53 | Bullish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 0.967x | Below |
| vs SMA200 | 0.941x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $93.16
- **Stop Loss:** $88.26 (5.3% risk)
- **Target:** $102.96 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $9,502.32
- **Portfolio %:** 9.50%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*